For the Inventor, By the Inventor

Enter assignee name

La Jolla, CA, United States of America

Epicentrx, Inc.

USPTO Granted Patents = 29

EPO Patents = 5

Forward Citations = 147

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Bryan T Oronsky (25 out of 29 patents)

Tony R Reid (12 out of 27 patents)

Jan Scicinski (10 out of 12 patents)

4. Christopher Larson (9 out of 13 patents)

5. Susan Knox (5 out of 13 patents)

6. Shoucheng Ning (4 out of 8 patents)

7. Louis F Cannizzo (4 out of 21 patents)

8. Scott Caroen (4 out of 4 patents)

9. Stephen P Velarde (3 out of 16 patents)

10. Kirstin F Warner (3 out of 15 patents)

11. Robert B Wardle (3 out of 14 patents)

12. Mark David Bednarski (3 out of 16 patents)

13. Arnold L Oronsky (2 out of 3 patents)

14. Neil C Oronsky (1 out of 3 patents)

15. Frans A Kuypers (1 out of 6 patents)

29 patents: Sort by Forward Citations

1. 12357608 - Methods and compositions utilizing RRx-001 combination therapy for radioprotection (2025-07-15),

2. 12357607 - Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (2025-07-15),

3. 12295976 - Personalized cancer vaccines (2025-05-13),

4. 12291726 - A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter (2025-05-06),

5. 12280123 - Recombinant adenoviruses carrying transgenes (2025-04-21),

6. 12109348 - Medication infusion devices, systems, and methods (2024-10-08),

7. 12054530 - Immunomodulatory fusion proteins (2024-08-06),

8. 12048793 - Medication infusion devices, systems, and methods (2024-07-30),

9. 12036247 - Multiple transgene recombinant adenovirus (2024-07-16),

10. 11999973 - Method for producing recombinant oncolytic adenovirus with modified E1a cancer-specific promoter (2024-06-04),

11. 11925617 - Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof (2024-03-12),

12. 11834492 - Human IL-10 receptor alpha fusion proteins (2023-12-05),

13. 11744859 - Compositions and methods for parenteral administration of therapeutic agents (2023-09-05),

14. 11701351 - Treatment of gliomas using organonitro compound combination therapy (2023-07-18),

15. 11660286 - Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products (2023-05-30),

EPICENTRX, INC. is a biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. With deep expertise in molecular biology and immunology, EPICENTRX is dedicated to revolutionizing cancer treatment by targeting the immune system to fight cancer cells. Through cutting-edge research and innovative drug development, EPICENTRX aims to improve patient outcomes and make a significant impact in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

29 Patents

#24 in La Jolla, CA

#2,687 in California

#11,209 in US

#21,869 in the World

La Jolla, CA, United States of America

Epicentrx, Inc.

Forward Citations = 147

26 inventors:

Bryan T Oronsky (25 out of 29 patents)

Tony R Reid (12 out of 27 patents)

Jan Scicinski (10 out of 12 patents)

4. Christopher Larson (9 out of 13 patents)

5. Susan Knox (5 out of 13 patents)

Please report any incorrect information to support@idiyas.com

Loading…